706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b

Alexey Berezhnoy; Hsin Wang; Na Cai; Hikmat Assi; Nicole Lapuyade; Madan Paidhungat; Kenneth Wong; Michael Krimm; Robert Dunn; Dylan Daniel; Marcia Belvin; Erwan Le Scolan

doi:10.1136/jitc-2021-SITC2021.706

Article info

Regular and Young Investigator Award Abstracts

Immune-Stimulants and Immune Modulators

706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b

Free

Authors

Alexey Berezhnoy CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Hsin Wang CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Na Cai CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Hikmat Assi CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Nicole Lapuyade CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Madan Paidhungat CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Kenneth Wong CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Michael Krimm CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Robert Dunn CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Dylan Daniel CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Marcia Belvin CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles
Erwan Le Scolan CytomX Therapeutics, South San Francisco, CA, United States PubMed articles Google scholar articles

Citation

Berezhnoy A, Wang H, Cai N, et al

706 Conditional cytokine therapeutics for tumor-selective biological activity: preclinical characterization of a dual-masked IFN-a2b

Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.706

Publication history

First published November 10, 2021.

Online issue publication

March 30, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Main menu

Authors

Citation

Publication history

Request permissions

Copyright information

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password